ក្រុមហ៊ុនបច្ចេកវិទ្យាជីវសាស្ត្រសំយោគ Amyris បង្ហាញពីវឌ្ឍនភាពក្នុងប្រតិបត្តិការផ្គត់ផ្គង់ធាតុផ្សំ

• អាមីរីស Inc (ផ្សារហ៊ុន NASDAQ: អេអឹមអេស), a synthetic biotechnology company, has completed the negotiation of key financial and business terms for the exclusive សិទ្ធិ to supply two of its ingredients. The transaction has an expected value of over $500 million.

• Both parties have agreed to confidentiality regarding further details about the transaction, which is subject to antitrust review under the Hart-Scott-Rodino Act (HSR) with a standard waiting period of thirty days.

• Amyris would continue to develop, scale and manufacture the ingredients. In addition, the parties are expected to enter a long-term R&D collaboration partnership to develop new molecules.

• “This is our third transaction of this nature and what we believe to be a strategic part of our business model for the value creation of our technology,” said CEO John Melo.

• The transaction is expected to sign and close early in the first quarter of 2023.

• សកម្មភាពតម្លៃ: AMRS shares are trading lower by 4.12% at $1.86 on the last check Tuesday.

• រូបថតរបស់ Via Company

មើលអ្វីផ្សេងបន្ថែមទៀតរបស់ Benzinga

កុំខកខានការជូនដំណឹងតាមពេលវេលាជាក់ស្តែងលើភាគហ៊ុនរបស់អ្នក – ចូលរួម ប្រូម៉ាណា ដោយ​ឥតគិតថ្លៃ! សាកល្បងឧបករណ៍ដែលនឹងជួយអ្នកឱ្យវិនិយោគកាន់តែឆ្លាតវៃ លឿនជាងមុន និងប្រសើរជាងមុន។.

© ២០២០ Benzinga.com ។ Benzinga មិនផ្តល់ដំបូន្មានវិនិយោគទេ។ រក្សា​រ​សិទ្ធ​គ្រប់យ៉ាង។